• 出版社/出版日：Mordor Intelligence / 2020年4月20日
|Single User||￥442,000 (USD4,250)||▷ お問い合わせ|
|Team User||￥494,000 (USD4,750)||▷ お問い合わせ|
|Corporate License||￥780,000 (USD7,500)||▷ お問い合わせ|
The Enzyme Replacement Therapy Market is expected to register a CAGR of 7.7% during the forecast period. The increasing burden of rare diseases and initiatives taken by the government and others for rare diseases is expected to be a key contributor in the enzyme replacement therapy market growth. In 2018, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) granted marketing authorization for Lamzede used for treating Alpha-mannosidosis in the European Union. According to the EURORDIS, currently there are over 6000 rare disease in existence and around 30 million of the population in Europe is affected by it. Furthermore, atleast 80% of these rare disorders are chronic and life threatening. Hence, the treatment of rare diseases is of utmost importance, thereby boosting the enzyme replacement therapy market growth.
Key Market Trends
Agalsidase Alfa Segment is Expected to Hold a Major Market Share in the Enzyme Replacement Therapy Market
Fabry is an X-linked rare disease that comes in the group of lysosomal storage disorders. Algasidase Alfa is a recombinant formulation of human a-galactosidase (AGAL), it is being used for the treatment of Fabry disease. Currently, this enzyme is manufactured by the Shire, a subsidiary of Takeda Pharmaceutical Company with the brand name Replagal. To date, Replagal has received approval for marketing and production in Canda, the United Kingdom and other parts of Europe.
Furthermore, according to the study published in JIMD, in 2019, Fabry disease is more prevalent in the population which is undergoing dialysis. Approximately 1.2% of the dialysis population has been reported with Fabry disease worldwide. Hence, the high prevalence of Fabry disease emerges the need for treatment which is expected to boost up the enzyme replacement therapy market in algasidase alfa segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America expected to hold a major market share in the global artificial disc market owing to initiatives taken by the government and other organizations related to rare diseases and its treatment. For instance, the National Institutes of Health awarded approximately USD 31 million in grants during 2019 to the 20 teams, including five new groups of scientists, clinicians, patients, families, and patients, to study a wide range of rare diseases. Additional USD 7 million has been provided to the data coordinating centers to support the research efforts. Furthermore, the National Center for Advancing Translational Sciences (NCATS), one of the centers of the National Institute of Health is solely dedicated to the treatment of patients with rare diseases. Also, the higher prevalence of rare diseases is expected to propel the enzyme replacement therapy in North America. According to the Genetic and Rare Diseases Information Center (GARD), at present, there are around 25 to 35 million people in the United States that suffer from rare diseases.
Companies are taking strategic initiatives related to enzyme replacement therapy to grow their presence in the market. For instance, recently Takeda exhibited its recent advances for lysosomal storage disorders at World Symposium in Orlando. Some of the key players which are currently dominating the market are Genzyme Corporation, Pfizer Inc., Leadiant Biosciences, Inc., Biomarin Pharmaceutical Inc., Takeda Pharmaceutical Company Limited, Protalix Biotherapeutics, Amicus Therapeutics, and Johnson & Johnson Services, Inc.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Rare Diseases
4.2.2 Increasing Government Initiatives for Rare Diseases
4.3 Market Restraints
4.3.1 High Cost of the Treatment
4.4 Porters Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Enzyme Type
5.1.1 Agalsidase Alfa
5.1.2 Agalsidase Beta
5.1.4 Other Enzyme Types
5.2 By Application
5.2.1 Gaucher disease
5.2.2 Pompe disease
5.2.3 Fabry Disease
5.3.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle-East and Africa
5.3.5 South America
220.127.116.11 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amicus Therapeutics
6.1.2 Biomarin Pharmaceutical Inc.
6.1.3 Genzyme Corporation
6.1.4 Johnson & Johnson
6.1.5 Leadiant Biosciences, Inc.
6.1.6 Pfizer Inc.
6.1.7 Protalix Biotherapeutics
6.1.8 Takeda Pharmaceutical Company Limited
7 MARKET OPPORTUNITIES AND FUTURE TRENDS